Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
Leukemia ( IF 11.4 ) Pub Date : 2017-11-16 , DOI: 10.1038/leu.2017.330 A Pardanani,J Gotlib,A W Roberts,M Wadleigh,S Sirhan,J Kawashima,J A Maltzman,L Shao,V Gupta,A Tefferi
Leukemia ( IF 11.4 ) Pub Date : 2017-11-16 , DOI: 10.1038/leu.2017.330 A Pardanani,J Gotlib,A W Roberts,M Wadleigh,S Sirhan,J Kawashima,J A Maltzman,L Shao,V Gupta,A Tefferi
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
中文翻译：
JAK1和JAK2抑制剂莫米洛替尼治疗骨髓纤维化的长期疗效和安全性
JAK1和JAK2抑制剂莫米洛替尼治疗骨髓纤维化的长期疗效和安全性
更新日期：2017-11-16
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis, Published online: 16 November 2017; doi:10.1038/leu.2017.330
中文翻译：
JAK1和JAK2抑制剂莫米洛替尼治疗骨髓纤维化的长期疗效和安全性
JAK1和JAK2抑制剂莫米洛替尼治疗骨髓纤维化的长期疗效和安全性
JAK1和JAK2抑制剂莫米洛替尼治疗骨髓纤维化的长期疗效和安全性，在线发布：2017年11月16日；doi：10.1038 / leu.2017.330
京公网安备 11010802027423号